TSC22 Domain Family Protein 3
L.HoghooghiV.PlemelJ
6 The phase 2 monotherapy dose-finding trial by Lau and colleagues established that once-weekly cagrilintide up to 4.5 mg produced dose-dependent weight loss about 10.8% at the top dose over 26 weeks with a gastrointestinal side-effect profile (nausea and related symptoms) that is the clinical fingerprint of a gut-slowing, satiating mechanism
The PCAC is currently meeting to discuss seven peptides: BPC-157 KPV TB-500 MOTS-c Emideltide (also called DSIP) Semax Epitalon These peptides (plus five more) were previously on the 503A Bulk Drug Substances list, meaning they were able to be prescribed and compounded
Eur J Pharm Biopharm
For example, a 2011 study in rats found that the peptide successfully healed various lesions and promoted healthy weight gain in models of short-bowel syndrome.14 Additionally, as researchers note in the aforementioned 2016 review on BPC-157 and the gut-brain axis, BPC 157 was successful in the therapy of GI tract, periodontitis, liver and pancreas lesions, and in the healing of various tissues and wounds. Its also written in the review that the peptide acts as a mediator of Roberts cytoprotection, defined as the counteraction of the lesions arising from direct detrimental contact with a noxious agent.7 15 Insider Tip: Though there has been some small-scale positive human research on BPC-157, most of the peptides potential uses are based on the outcomes of animal or cell studies
